Table 1.
Clinical and demographic characteristics of healthy subjects and relapsing-remitting multiple sclerosis (RRMS) patients regarding optic neuritis (ON) antecedent. Differences were tested using generalized estimating equations accounting for sex, age, and within-patient intereye correlation.
| Healthy subjects | RRMS | ON eyes | Non-ON eyes | P (healthy versus RRMS) | P (healthy versus ON eyes) | P (healthy versus non-ON eyes) | P (ON versus non-ON eyes) | |
|---|---|---|---|---|---|---|---|---|
| N = 70 | N = 70 | N = 36 | N = 104 | |||||
| Mean ± SD | ||||||||
| Age (years) | 37 ± 10 | 40 ± 10 | 42 ± 9 | 40 ± 11 | 0.077 | 0.008 | 0.077 | 0.302 |
| Female (%) | 40 (57%) | 44 (63%) | 14 (78%) | 30 (58%) | 0.387 | 0.627 | 0.363 | 0.552 |
| LogMAR BCVA | 0.00 ± 0.02 | 0.04 ± 0.18 | 0.10 ± 0.26 | 0.02 ± 0.14 | 0.006 | 0.023 | 0.115 | 0.083 |
| EDSS score | N/A | 2.42 ± 1.72 | 2.43 ± 1.61 | 2.41 ± 1.76 | N/A | N/A | N/A | 0.873 |
| Years since diagnosis | N/A | 6.82 ± 6.95 | 7.31 ± 6.25 | 6.66 ± 7.19 | N/A | N/A | N/A | 0.754 |
| MD (in dB) | N/A | −2.7 ± 3.8 | −3.8 ± 5.2 | −2.4 ± 3.1 | N/A | N/A | N/A | <0.001 |
| Average pRNFL (Sp; in μm) | 99.3 ± 8.7 | 87.8 ± 13.8 | 79.6 ± 13.6 | 90.7 ± 12.7 | <0.001 | <0.001 | <0.001 | <0.001 |
| Temporal pRNFL (Sp; in μm) | 71.4 ± 10.6 | 58.8 ± 16.0 | 50.2 ± 16.2 | 61.9 ± 14.8 | <0.001 | <0.001 | <0.001 | <0.001 |
| PMB pRNFL (Sp; in μm) | 54.9 ± 7.6 | 44.4 ± 11.4 | 38.8 ± 11.8 | 46.4 ± 10.7 | <0.001 | <0.001 | <0.001 | <0.001 |
| Average pRNFL (Ci; in μm) | 93.9 ± 8.5 | 84.9 ± 12.5 | 78.9 ± 13.0 | 87.0 ± 11.7 | <0.001 | <0.001 | <0.001 | <0.001 |
| Temporal pRNFL (Ci; in μm) | 64.7 ± 9.5 | 54.2 ± 13.8 | 47.4 ± 14.0 | 56.6 ± 13.0 | <0.001 | <0.001 | <0.001 | <0.001 |
| Average GCIPL (Ci; in μm) | 83.8 ± 5.9 | 72.2 ± 11.3 | 66.4 ± 10.9 | 74.3 ± 10.7 | <0.001 | <0.001 | <0.001 | <0.001 |
| Minimum GCIPL (Ci; in μm) | 81.9 ± 6.1 | 68.1 ± 12.9 | 61.4 ± 13.2 | 70.4 ± 12.0 | <0.001 | <0.001 | <0.001 | <0.001 |
| Superior GCIPL (Ci; in μm) | 80.5 ± 6.2 | 73.0 ± 11.7 | 66.7 ± 11.4 | 75.2 ± 11.1 | <0.001 | <0.001 | <0.001 | <0.001 |
| Superonasal GCIPL (Ci; in μm) | 85.5 ± 6.3 | 73.0 ± 11.7 | 65.8 ± 10.8 | 75.5 ± 11.0 | <0.001 | <0.001 | <0.001 | <0.001 |
| Inferonasal GCIPL (Ci; in μm) | 84.0 ± 6.3 | 72.0 ± 12.2 | 64.5 ± 11.8 | 74.6 ± 11.2 | <0.001 | <0.001 | <0.001 | <0.001 |
| Inferior GCIPL (Ci; in μm) | 82.7 ± 6.2 | 71.6 ± 12.0 | 65.6 ± 12.5 | 73.7 ± 11.1 | <0.001 | <0.001 | <0.001 | <0.001 |
| Inferotemporal GCIPL (Ci; in μm) | 83.8 ± 6.1 | 73.3 ± 11.0 | 68.6 ± 12.3 | 74.9 ± 10.1 | <0.001 | <0.001 | <0.001 | <0.001 |
| Superotemporal GCIPL (Ci; in μm) | 82.4 ± 6.5 | 72.3 ± 10.9 | 67.0 ± 11.0 | 74.2 ± 10.4 | <0.001 | <0.001 | <0.001 | <0.001 |
SD: standard deviation; BCVA: best corrected visual acuity; EDSS: Expanded Disability Status Scale; MD: 24-2 SITA Standard Visual Field Mean Deviation; pRNFL: peripapillary retinal nerve fiber layer; Sp: Spectralis OCT; PMB: papillomacular bundle; Ci: Cirrus OCT; GCIPL: ganglion cell and inner plexiform layers.